Biosimilar erythropoietin in anemia treatment (BEAT) - Efficacy and safety of a 1:1 dose conversion from EPREX<sup>®</sup>to EPIAO<sup>®</sup>in patients with end-stage renal disease on hemodialysis: A prospective, randomized, double blind, parallel group study
Background: EPREX®/ERYPO®/PROCRIT® (epoetin alfa, Janssen-Cilag GmbH) was the first available recombinant human erythropoietin (rHuEPO) and was universally reference product as per the recommendation provided by European Medicines Agency. EPIAO® is a biosimilar formulation of EPREX®, and making it a...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Review |
| Published: |
2023
|
| Subjects: | |
| Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/85368 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Mahidol University |